CYTOSORBENTS CORPORATION (CTSO) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 14.15M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 3.09M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 37.96M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $14.15M | $3.09M | (m) | (m) | $37.96M | (m) |
| 2026-03-31 | (m) | (m) | $6.65M | $10.31M | (m) | (m) | $40.56M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $16.67M | (m) | (m) | $44.18M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $14.57M | (m) | (m) | $45.75M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $14.38M | (m) | (m) | $47.99M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $14.19M | (m) | (m) | $50.78M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $14.00M | (m) | (m) | $47.37M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $13.81M | (m) | (m) | $47.80M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $13.67M | (m) | (m) | $53.43M | (m) |
| 2024-03-31 | (m) | (m) | $2.50M | $1.93M | (m) | (m) | $47.07M | (m) |
| 2023-12-31 | (m) | (m) | $2.50M | $2.54M | (m) | (m) | $53.26M | (m) |
| 2023-09-30 | (m) | (m) | $833.33K | $4.20M | (m) | (m) | $47.58M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $5.02M | (m) | (m) | $52.44M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $5.00M | (m) | (m) | $63.23M | (m) |
| 2020-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $89.95M | (m) |
| 2020-09-30 | (m) | (m) | $9.17M | $5.99M | (m) | (m) | $104.28M | (m) |
| 2020-06-30 | (m) | (m) | $6.67M | $8.46M | (m) | (m) | $49.26M | (m) |
| 2020-03-31 | (m) | (m) | $4.17M | $10.92M | (m) | (m) | $44.23M | (m) |
| 2019-12-31 | (m) | (m) | $1.67M | $13.39M | (m) | (m) | $27.38M | (m) |
| 2019-09-30 | (m) | (m) | $3.13M | $11.89M | (m) | (m) | $28.68M | (m) |
| 2019-06-30 | (m) | (m) | $833.33K | $9.16M | (m) | (m) | $28.48M | (m) |
| 2019-03-31 | (m) | (m) | $1.67M | $8.30M | (m) | (m) | $30.99M | (m) |
| 2018-12-31 | (m) | (m) | $666.67K | $9.27M | (m) | (m) | $32.75M | (m) |
| 2018-09-30 | (m) | (m) | $0.00 | $9.92M | (m) | (m) | $34.25M | (m) |
| 2018-06-30 | (m) | (m) | $0.00 | $9.89M | (m) | (m) | $34.95M | (m) |
| 2018-03-31 | (m) | (m) | $0.00 | $9.87M | (m) | (m) | $28.30M | (m) |
| 2017-12-31 | (m) | (m) | $4.00M | $5.99M | (m) | (m) | $24.10M | (m) |
| 2017-09-30 | (m) | (m) | $3.00M | $6.97M | (m) | (m) | $22.22M | (m) |
| 2017-06-30 | (m) | (m) | $2.00M | $7.94M | (m) | (m) | $22.09M | (m) |
| 2017-03-31 | (m) | (m) | $1.25M | $3.68M | (m) | (m) | $8.29M | (m) |
| 2016-12-31 | (m) | (m) | $833.33K | $4.08M | (m) | (m) | $9.69M | (m) |
| 2016-09-30 | (m) | (m) | $416.67K | $4.48M | (m) | (m) | $10.86M | (m) |
| 2016-06-30 | (m) | (m) | (m) | $4.88M | (m) | (m) | $12.71M | (m) |
| 2015-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $11.25M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |